Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3906645 | Urology | 2006 | 5 Pages |
Abstract
Judicious broadening of the clinical selection criteria may allow a greater number of patients to be eligible for permanent prostate brachytherapy monotherapy by including patients whose risk of having adverse pathologic features is comparable to that of patients currently deemed suitable for permanent prostate brachytherapy monotherapy. Prospective assessment of oncologic outcomes of such an approach is required.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Shomik Sengupta, Brian J. Davis, Lance A. Mynderse, Thomas J. Sebo, John C. Cheville, Christine M. Lohse, David W. Hillman, Michael G. Haddock, Torrence M. Wilson,